S-1/A: Cosmos Health Amends S-1 Filing, Details $7.5 Million Offering and Financials

Cosmos Health Inc. amends its S-1 filing, outlining a proposed $7.5 million offering and providing updates on its financial condition and recent transactions.

Summary

• Cosmos Health Inc. has filed an amendment to its S-1 registration statement.
• The document details a proposed offering with a maximum aggregate offering price of $7.5 million.
• The offering includes common stock, pre-funded warrants, and common warrants.
• The company plans to use Rule 457(c) to calculate the registration fee, based on a share price of $0.703.
• The document also includes financial statements and information about recent acquisitions, related party transactions, and debt agreements.
• Cosmos Health Inc. is an international healthcare group engaged in nutraceuticals, pharmaceuticals, and healthcare distribution.
• The company's management expresses substantial doubt about its ability to continue as a going concern for the next twelve months.
• The company plans to expand brand name products, product portfolio, and evaluate acquisition targets to expand distribution.
• Cosmos Health Inc. intends to vertically integrate the supply chain distribution network and access capital markets through equity offerings.
• The company sold 901,488 shares of common stock for net proceeds of $629,426 pursuant to an at-the-market sales agreement.
• The company entered into a Warrant Inducement Letter with an investor pursuant to which the Company issued 9,748,252 new warrants and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977.
• The company's subsidiary Cosmofarm SA entered into an agreement with a third-party lender in the principal amount of 400,000 ($432,760).

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a going concern warning and reliance on capital raising activities, overshadowing any positive aspects.

Positives

• The company is expanding its brand name products to the market.
• The company is expanding the current product portfolio.
• The company is evaluating acquisition targets to expand distribution.
• The company intends to vertically integrate the supply chain distribution network.
• The company has signed multiple distribution agreements for its SPL products in Europe and Asia.
• The company has a variety of contract manufacturing agreements through its subsidiary, Cana Laboratories Holdings (Cyprus) Limited.

Negatives

• The company's management expresses substantial doubt about its ability to continue as a going concern.
• The company's revenues are not able to sustain its operations.
• Concerns exist regarding the company's ability to meet its obligations as they become due.
• The company had a net loss of $6,639,935 for the nine months ended September 30, 2024.
• The company had net cash used in operations of $3,883,215 for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $104,479,192 as of September 30, 2024.

Risks

• The company is subject to risks common to smaller commercial companies, including dependence on key individuals and products.
• The company faces difficulties inherent in the development of a commercial market.
• The company needs to obtain additional capital.
• The company faces competition from larger companies and other pharmaceutical and health care companies.
• Management cannot provide any assurances that the company will be successful in accomplishing any of its plans.
• The ability of the company to continue as a going concern is dependent upon its ability to successfully accomplish its plans and secure other sources of financing and attain profitable operations.

Future Outlook

Management plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution; the Company intends to vertically integrate the supply chain distribution network and further access the capital markets to raise additional funds through equity offerings.

Management Comments

• It is the managements opinion that these conditions raise substantial doubt about the Companys ability to continue as a going concern for a period of twelve months from the date of this filing.
• Management evaluated the above conditions which raise substantial doubt about the Companys ability to continue as a going concern to determine if it can meet its obligations for the subsequent twelve months from the date of this filing.
• Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products.
• However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

Industry Context

The announcement reflects the challenges faced by smaller pharmaceutical and nutraceutical companies in a competitive market, particularly regarding access to capital and achieving sustainable profitability.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• However, the mention of dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, and competition from larger companies are common challenges faced by smaller companies in the pharmaceutical and healthcare industries.
• Comparable companies in the nutraceutical sector include companies like Herbalife Nutrition, Nu Skin Enterprises, and USANA Health Sciences, which have established global distribution networks and brand recognition.
• In the pharmaceutical sector, comparable companies include generic drug manufacturers and OTC medication providers, which often face pricing pressures and regulatory hurdles.

Legal Proceedings

• A lawsuit dated April 5, 2018 against the Companys subsidiary Cana by a former employee before the Athens court of instance was initially heard on October 12, 2018.
• The former employee was seeking that the termination of her employment contract to be considered null and void and was requesting compensation for late wages and moral damages.
• Following numerous appeals, Judgment No. 1192/2024 was issued on September 26, 2023, which as explicitly stated by our legal counsel, requires CANA to rehire the former employee with the threat of a penalty of 200 for each day of non-compliance.
• Our subsidiary, Cana Laboratories, has two pending lawsuits against Euaggelismos Hospital for a total sum of EUR 526,436 due to unpaid bills.
• Our subsidiary, Cana Laboratories, has an unasserted claim against Papanikolaou Hospital for a total sum of EUR 89,300 due to unpaid bills, which will be asserted through a lawsuit.

Related Party Transactions

• The Company had a prepaid balance of $6,393,642 to Doc Pharma related to purchases of inventory and pharmaceutical and nutraceutical licenses to be purchased.
• The Company had an accounts payable balance to Doc Pharma of $72,968.
• The Company had a receivable balance of $2,448,517 from Doc Pharma S.A.
• The Company purchased a total of $510,711 of products from Doc Pharma S.A.
• The Company had $581,862 revenue from Doc Pharma.
• The Company has a loan agreement with Doc Pharma for 4,000,000 ($4,279,200).
• The Company had a prepaid balance of $194,215 to Panagiotis Kozaris for shares owned.
• The Company issued 120,000 shares of common stock to Basotho Investment Limited for services rendered.
• The Company has a receivable balance of $1,123,835 from Pharmacy & More, owned by Maria Kozari.
• The Company has a balance of $731,000 relating to unpaid salaries and bonuses due to Grigorios Siokas, the CEO of the Company and $188,000 due to George Terzis, the CFO of the Company.
• The Company has a net payable balance of $29,832 due to Konstantinos Gaston Kanaroglou, former manager and current employee of the Companys wholly owned subsidiary Cana.

Stakeholder Impact

• Shareholders face potential dilution from the proposed offering and the exercise of warrants.
• Employees may be affected by the company's cost-cutting measures and restructuring efforts.
• Customers and suppliers may experience disruptions due to the company's financial instability.
• Creditors face increased risk of non-payment or delayed payments.

Next Steps

• The company intends to make substantial efforts to receive additional debt financing through its subsidiary, Cosmofarm SA.
• The company plans to raise additional equity funds.
• The company is considering postponing certain repayments of suppliers and creditors.
• The company intends to execute a cumulative SPA for shares owned by Panagiotis Kozaris during 2024.
• The Company plans to acquire Pharmacy & More within fiscal year 2024.

Key Dates

Keywords

Cosmos Health, S-1 Filing, Offering, Warrants, Financials, Going Concern, Acquisition, Distribution, Equity, Debt, Pharmaceuticals, Nutraceuticals